ArticleHIV medicine2020
Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017.
Article in HIV medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Talaromyces marneffei, Coccidioides species, and Paracoccidioides species-a systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- GastrointestinalFrontiers in immunology · 2022Pooled it
- Positive Syphilis Serology With Concurrent Disseminated Talaromycosis marneffei in a Patient With HIV: A Case Report.The American journal of case reports · 2026Article
- An Interpretable Machine Learning Model for Predicting the Presence of Talaromycosis in HIV Patients Lacking Skin Lesions.Mycopathologia · 2026Article
- Epidemiology and factors associated with Talaromyces marneffei detection in the mainland of China, 2022-2024: a cross-sectional study of hospitalized patients.BMC public health · 2026Article
- AIDS patients with Talaromycosis Marneffei exhibit inflammatory activation and depletion in their peripheral blood monocytes.PLoS neglected tropical diseases · 2026Article
- Sequential Organ Failure Assessment (SOFA) score and quick SOFA(qSOFA) predict 30-day mortality in patients with HIV-associated Talaromycosis: A multicenter retrospective cohort study.PLoS neglected tropical diseases · 2026Article
- Two new clinical diagnostic models for Talaromycosis marneffei in AIDS patients within 48 h: evaluation of performance and comparison with previous models.BMC infectious diseases · 2026Article
- Recent Advances in the Diagnosis of Talaromycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Prevalence of Fungemia in People with HIV: A Systematic Review and Meta-Analysis.Microorganisms · 2026Review
- Successful Rescue Therapy for Talaromycosis Complicated by Severe Acute Hepatorenal Failure with Hepatic Encephalopathy in an HIV/HCV-Coinfected Patient: A Case Report.Infection and drug resistance · 2026Article
- Environmental transmission from bamboo rats: Mapping current and future talaromycosis risk in China under climate change.One health (Amsterdam, Netherlands) · 2025Article
- Prognostic model of HIV-associated talaromycosis in south China: A large-scale retrospective study.PLoS neglected tropical diseases · 2025Article
- Endemic Mycoses for Pulmonary Clinicians: From Nodules to ARDS.CHEST pulmonary · 2025Review
- PANoptosis-mediated mechanisms underlying AST elevation in Talaromyces marneffei infection.PLoS neglected tropical diseases · 2025Article
- Comparative performance of a commercial and in-house Mp1p antigen-detecting enzyme immunoassay for the rapid diagnosis of talaromycosis.PLoS neglected tropical diseases · 2025Article
- Clinical Characteristics and Prognosis of AIDS Complicated with Talaromycosis marneffei Infection: a Single-Center Retrospective Study.Infectious diseases and therapy · 2025Article
- Multicenter Case-Control Study of Behavioral, Environmental, and Geographic Risk Factors for Talaromycosis, Vietnam.Emerging infectious diseases · 2025Article
- Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies.Journal of fungi (Basel, Switzerland) · 2025Review
- Clinical features of talaromycosis in people living with HIV/AIDS (PWHA) and patients with anti-interferon-γ autoantibodies.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 4 countries.
Funding
Abstract
objectivesTalaromycosis is an invasive mycosis endemic to Southeast Asia. This study aimed to investigate the epidemiology, clinical features and prognostic factors of HIV-associated talaromycosis in Guangdong, China.
methodsWe retrospectively evaluated HIV patients hospitalized with histopathology- or culture-confirmed talaromycosis between 2011 and 2017. Factors associated with poor prognosis were identified using logistic regression.
resultsOverall, 1079 patients with HIV-associated talaromycosis were evaluated. Both the number and prevalence of talaromycosis among HIV admissions increased from 125 and 15.7% in 2011 to 253 and 18.8% in 2017, respectively, reflecting the increase in HIV admissions. Annual admissions peaked during the rainy season between March and August. Common clinical manifestations included fever (85.6%), peripheral lymphadenopathy (72.3%), respiratory symptoms (60.8%), weight loss (49.8%), skin lesions (44.5%) and gastrointestinal symptoms (44.3%). Common laboratory abnormalities were hypoalbuminaemia (98.6%), anaemia (95.6%), elevated aspartate aminotransferase level (AST) (76.9%), elevated alkaline phosphatase level (55.8%) and thrombocytopenia (53.7%). The median CD4 count was 9 cells/μL. Talaromyces marneffei was isolated from blood and bone marrow cultures of 66.6% and 74.5% of patients, respectively. The rate increased to 86.6% when both cultures were performed concurrently. At discharge, 14% of patients showed worsening conditions or died. Leucocytosis, thrombocytopenia, elevated AST, total bilirubin, creatinine and azole monotherapy independently predicted poor prognosis.
conclusionsThe incidence of HIV-associated talaromycosis has increased in Guangdong with the high HIV burden in China. Skin lesions were seen in less than half of patients. Induction therapy with azole alone is associated with higher mortality. Findings from this study should help to improve treatment of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.